NeuroVasc Technologies, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NeuroVasc Technologies, Inc. - overview
Established
2015
Location
Laguna Hills, CA, US
Primary Industry
Medical Devices & Equipment
About
NeuroVasc Technologies, Inc. is a medical device company focused on innovative solutions for neurovascular treatments, specifically aimed at enhancing patient outcomes in stroke care. Founded in 2015 in Laguna Hills, US, NeuroVasc Technologies specializes in neurovascular treatment devices. The company has completed 5 deals, with the most recent funding round occurring on February 27, 2020, where it raised USD 34 mn led by Shandong Weigao Group Medical Polymer Co.
, Limited. The CEO of the company is Wanli Jiang. NeuroVasc Technologies specializes in the design and development of innovative neurovascular treatment devices, including advanced catheter-based technologies like the eNVi-SR™, eNVoke™, and eNVac™ systems. These products are designed for mechanical thrombectomy and aspiration procedures to effectively remove blood clots from the neurovascular system.
The company serves a diverse client base, including hospitals and healthcare providers across more than 35 countries, ensuring improved access to critical stroke interventions in regions such as Europe, Asia, and South America. NeuroVasc Technologies operates on a B2B model, primarily engaging with healthcare institutions to supply their proprietary neurovascular devices. Sales transactions typically involve direct partnerships with hospitals and medical facilities, where devices are purchased per procedure or through contractual agreements for bulk supply. Their flagship products are integral to these transactions, enabling healthcare providers to offer advanced stroke treatment solutions.
Pricing structures are based on specific products utilized and volume agreements, which facilitate the integration of these innovative devices into treatment protocols without compromising patient care. NeuroVasc Technologies plans to expand its product line with new neurovascular devices targeted for release in the coming years. The company is also looking to enter new markets, particularly in Asia and South America, by the end of 2022. The recent funding of USD 34 mn will support these initiatives, enabling the development of new products and the expansion into these targeted geographic regions.
Current Investors
ShangBay Capital, Shandong Weigao Group Medical Polymer Co., Limited
Primary Industry
Medical Devices & Equipment
Sub Industries
Therapeutic Devices
Website
www.neurovasctechnologies.com
Company Stage
Series B
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.